Renviva Dialysis Center Of Clearwater, Llc is a medicare approved dialysis facility center in Clearwater, Florida and it has 2 dialysis stations. It is located in Pinellas county at 401 Corbett, Clearwater, FL, 33756. You can reach out to the office of Renviva Dialysis Center Of Clearwater, Llc at (727) 281-4490. This dialysis clinic is run as an Independent entity i.e it is not owned by any chain organization. Renviva Dialysis Center Of Clearwater, Llc has the following ownership type - Profit. It was first certified by medicare in April, 2017. The medicare id for this facility is 682619 and it accepts patients under medicare ESRD program.
| Name | Renviva Dialysis Center Of Clearwater, Llc |
|---|---|
| Location | 401 Corbett, Clearwater, Florida |
| No. of Dialysis Stations | 2 |
| Medicare ID | 682619 |
| Managed By | Independent |
| Ownership Type | Profit |
| Late Shifts | No |
| 401 Corbett, Clearwater, Florida, 33756 | |
| (727) 281-4490 | |
| Not Available |
News Archive
The consequences are dire for the health of a premature baby -; too much oxygen can cause blindness, and too little oxygen can cause brain damage and other negative health effects.
Catalent Pharma Solutions announced today that Catalent, Inc. has publicly filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock.
Juventas Therapeutics, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular disease, announces that the U.S. Food and Drug Administration (FDA) authorized commencement of a Phase II clinical trial evaluating the efficacy and safety of its lead product, JVS-100, for the treatment of critical limb ischemia (CLI).
By analyzing data from randomized clinical trials comparing blood transfusion approaches, Johns Hopkins experts, along with colleagues at Cleveland Clinic and NYU Langone Medical Center, endorse recommendations for blood transfusions that reduce blood use to improve patient safety and outcomes.
Thanks largely to the efforts of Johns Hopkins Medicine researchers, the American Heart Association recently announced recommendations for improving cardiovascular health outcomes in women before, during and after pregnancy.
› Verified 1 days ago
| Dialysis patients with Hemoglobin data | 3 |
News Archive
The consequences are dire for the health of a premature baby -; too much oxygen can cause blindness, and too little oxygen can cause brain damage and other negative health effects.
Catalent Pharma Solutions announced today that Catalent, Inc. has publicly filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock.
Juventas Therapeutics, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular disease, announces that the U.S. Food and Drug Administration (FDA) authorized commencement of a Phase II clinical trial evaluating the efficacy and safety of its lead product, JVS-100, for the treatment of critical limb ischemia (CLI).
By analyzing data from randomized clinical trials comparing blood transfusion approaches, Johns Hopkins experts, along with colleagues at Cleveland Clinic and NYU Langone Medical Center, endorse recommendations for blood transfusions that reduce blood use to improve patient safety and outcomes.
Thanks largely to the efforts of Johns Hopkins Medicine researchers, the American Heart Association recently announced recommendations for improving cardiovascular health outcomes in women before, during and after pregnancy.
› Verified 1 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular peritoneal dialysis at the center | 13 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 46 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 43 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
The consequences are dire for the health of a premature baby -; too much oxygen can cause blindness, and too little oxygen can cause brain damage and other negative health effects.
Catalent Pharma Solutions announced today that Catalent, Inc. has publicly filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock.
Juventas Therapeutics, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular disease, announces that the U.S. Food and Drug Administration (FDA) authorized commencement of a Phase II clinical trial evaluating the efficacy and safety of its lead product, JVS-100, for the treatment of critical limb ischemia (CLI).
By analyzing data from randomized clinical trials comparing blood transfusion approaches, Johns Hopkins experts, along with colleagues at Cleveland Clinic and NYU Langone Medical Center, endorse recommendations for blood transfusions that reduce blood use to improve patient safety and outcomes.
Thanks largely to the efforts of Johns Hopkins Medicine researchers, the American Heart Association recently announced recommendations for improving cardiovascular health outcomes in women before, during and after pregnancy.
› Verified 1 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Renviva Dialysis Center Of Clearwater, Llc with elevated calcium levels.
| Patients with hypercalcemia | 14 |
| Hypercalcemia patient months | 52 |
| Patients with Serumphosphor | 15 |
| Patients with Serumphosphor less than 3.5 mg/dL | 3 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 26 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 46 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 23 |
| Patients with Serumphosphor greater than 7 mg/dL | 3 |
News Archive
The consequences are dire for the health of a premature baby -; too much oxygen can cause blindness, and too little oxygen can cause brain damage and other negative health effects.
Catalent Pharma Solutions announced today that Catalent, Inc. has publicly filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock.
Juventas Therapeutics, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular disease, announces that the U.S. Food and Drug Administration (FDA) authorized commencement of a Phase II clinical trial evaluating the efficacy and safety of its lead product, JVS-100, for the treatment of critical limb ischemia (CLI).
By analyzing data from randomized clinical trials comparing blood transfusion approaches, Johns Hopkins experts, along with colleagues at Cleveland Clinic and NYU Langone Medical Center, endorse recommendations for blood transfusions that reduce blood use to improve patient safety and outcomes.
Thanks largely to the efforts of Johns Hopkins Medicine researchers, the American Heart Association recently announced recommendations for improving cardiovascular health outcomes in women before, during and after pregnancy.
› Verified 1 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 1 |
| Patient months included in arterial venous fistula and catheter summaries | 6 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer |
News Archive
The consequences are dire for the health of a premature baby -; too much oxygen can cause blindness, and too little oxygen can cause brain damage and other negative health effects.
Catalent Pharma Solutions announced today that Catalent, Inc. has publicly filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock.
Juventas Therapeutics, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular disease, announces that the U.S. Food and Drug Administration (FDA) authorized commencement of a Phase II clinical trial evaluating the efficacy and safety of its lead product, JVS-100, for the treatment of critical limb ischemia (CLI).
By analyzing data from randomized clinical trials comparing blood transfusion approaches, Johns Hopkins experts, along with colleagues at Cleveland Clinic and NYU Langone Medical Center, endorse recommendations for blood transfusions that reduce blood use to improve patient safety and outcomes.
Thanks largely to the efforts of Johns Hopkins Medicine researchers, the American Heart Association recently announced recommendations for improving cardiovascular health outcomes in women before, during and after pregnancy.
› Verified 1 days ago